Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | SORD | Q00796 | 7/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.44 |
| ▸ | HTR3B | O95264 | 3/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919248 | 0.80 | HRH3 (0.59) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| Hydrochloric Acid SCHEMBL6978271 | 0.79 | HRH3 (0.58) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| SCHEMBL6293482 | 0.77 | HRH3 (0.55) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| SCHEMBL7140223 | 0.76 | HRH3 (0.51) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| SCHEMBL6224825 | 0.75 | HRH3 (0.54) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| SCHEMBL3640716 | 0.74 | HRH3 (0.52) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| SCHEMBL6684708 | 0.73 | ADRB1 (0.51) | HRH3HTR3AALDH1A1KDM4EUSP2 | |
| SCHEMBL26669204 | 0.72 | HRH3 (0.56) | HRH3SORDHRH4CYP1A2HSD17B10 | |
| SCHEMBL23458788 | 0.71 | HRH3 (0.65) | HRH3HRH4CYP1A2HSD17B10HTR3A | |
| SCHEMBL6976678 | 0.71 | HRH3 (0.65) | HRH3SORDHRH4CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| US-20090280192-A1 | METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | Wands, Jack R. | 2009-11-12 | — | — | US | disclosed |
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| US-7300927-B2 | Method for treating or preventing Alzheimer's disease | Esmond, Robert W. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| CN-1876648-A | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1267424-C | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | BIOVITRUM AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| US-20050043242-A1 | Method for treating or preventing Alzheimer's disease | Wands, Jack | 2005-02-24 | — | — | US | disclosed |
| EP-1006794-A4 | A METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | ESMOND ROBERT W (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040060077-A1 | Method for treating or preventing Alzheimer's disease | ESMOND ROBERT W (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
| EP-1006794-A1 | A METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | Esmond, Robert W. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998039967-A1 | A METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-09-17 | — | — | WO | disclosed |
| US-4980350-A | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO., INC. (US) | 1990-12-25 | — | — | US | disclosed |
| US-4980350-A | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO., INC. (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0330263-A1 | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0330263-A1 | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | HRH3 2101/4885SORD 3887/4885HRH4 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.